| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Laura Lammers, Bree Zehm, Richard William. Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada. BMC psychiatry. vol 13. 2015-01-06. PMID:23718192. |
the objectives of the present study were to compare safety and outcomes in patients with schizophrenia initiated on risperidone long-acting injection (rlai) or first generation antipsychotic injections (fgai) at a mental health centre in british columbia. |
2015-01-06 |
2023-08-12 |
Not clear |
| Hong-tao Song, Xin-yang Sun, Liang Zhang, Lin Zhao, Zhong-min Guo, Hui-min Fan, Ai-fang Zhong, Wei Niu, Yun-hua Dai, Li-yi Zhang, Zheng Shi, Xiao-ping Liu, Jim L. A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. Journal of psychiatric research. vol 54. 2014-12-30. PMID:24694668. |
a total of 20 schizophrenia patients absent of antipsychotics and 20 age-and gender-matched normal controls were enrolled, and tested for 9 schizophrenia-associated microrna (mir-30e, mir-34a, mir-181b, mir-195, mir-346, mir-432, mir-7, mir-132 and mir-212) expression levels in plasma using quantitative rt-pcr and for symptomatology improvement using positive and negative syndrome scale (panss) before and after treatment (olanzapine, quetiapine, ziprasidone and risperidone) for the patients only. |
2014-12-30 |
2023-08-13 |
human |
| Daniel Umbricht, Richard S E Keefe, Stephen Murray, David A Lowe, Richard Porter, George Garibaldi, Luca Santarell. A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 7. 2014-12-29. PMID:24549101. |
this 8-week (week 1, inpatient; weeks 2-8, outpatient), double-blind, randomized study used measurement and treatment research to improve cognition in schizophrenia (matrics) guidelines to investigate the nicotinic α7 partial agonist rg3487 (formerly mem3454) in cias; 215 patients with chronic stable schizophrenia received placebo or rg3487 (5, 15, or 50 mg) added to ongoing treatment with risperidone, paliperidone, or aripiprazole. |
2014-12-29 |
2023-08-12 |
Not clear |
| Wagner F Gattaz, João Alberto de Oliveira Campos, Acioly L T Lacerda, Elaine Henna, Sandra Inês Ruschel, Rodrigo A Bressan, Irismar Reis de Oliveira, Fábio Lopes Rocha, Hamilton M Grabowski, Ernindo Sacomani, Mario R Louzã, João Quevedo, Hélio Elkis, Dirceu Zorzetto Filho, Cintia de Azevedo-Marques Périco, Fábio Lorea Lawson, José Carlos Appolinári. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Current medical research and opinion. vol 30. issue 4. 2014-12-17. PMID:24289141. |
switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the rispali study. |
2014-12-17 |
2023-08-12 |
Not clear |
| Wagner F Gattaz, João Alberto de Oliveira Campos, Acioly L T Lacerda, Elaine Henna, Sandra Inês Ruschel, Rodrigo A Bressan, Irismar Reis de Oliveira, Fábio Lopes Rocha, Hamilton M Grabowski, Ernindo Sacomani, Mario R Louzã, João Quevedo, Hélio Elkis, Dirceu Zorzetto Filho, Cintia de Azevedo-Marques Périco, Fábio Lorea Lawson, José Carlos Appolinári. Switching from oral risperidone to flexibly dosed oral paliperidone extended-release: core symptoms, satisfaction, and quality of life in patients with stable but symptomatic schizophrenia: the RISPALI study. Current medical research and opinion. vol 30. issue 4. 2014-12-17. PMID:24289141. |
the purpose of this prospective study was to evaluate the effects of switching from oral risperidone to flexibly dosed oral paliperidone extended-release (er) in brazilian adults with schizophrenia because of lack of efficacy, intolerability, or nonadherence after a minimum trial of 30 days on adequate (labeled) doses of oral risperidone, according to individual clinical judgment. |
2014-12-17 |
2023-08-12 |
Not clear |
| Hiroshi Kimura, Nobuhisa Kanahara, Naoya Komatsu, Minoru Ishige, Katsumasa Muneoka, Masayuki Yoshimura, Hiroshi Yamanaka, Tomotaka Suzuki, Hideki Komatsu, Tsuyoshi Sasaki, Tasuku Hashimoto, Tadashi Hasegawa, Akihiro Shiina, Masatomo Ishikawa, Yoshimoto Sekine, Tetsuya Shiraishi, Hiroyuki Watanabe, Eiji Shimizu, Kenji Hashimoto, Masaomi Iy. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. Schizophrenia research. vol 155. issue 1-3. 2014-12-17. PMID:24667073. |
a prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis. |
2014-12-17 |
2023-08-12 |
Not clear |
| Seyed Mohammad Reza Hosseini, Mehdi Farokhnia, Farzin Rezaei, Amirhossein Gougol, Habibeh Yekehtaz, Negar Iranpour, Bahman Salehi, Mina Tabrizi, Masih Tajdini, Ali Ghaleiha, Shahin Akhondzade. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 6. 2014-12-16. PMID:24636461. |
intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. |
2014-12-16 |
2023-08-12 |
human |
| Seyed Mohammad Reza Hosseini, Mehdi Farokhnia, Farzin Rezaei, Amirhossein Gougol, Habibeh Yekehtaz, Negar Iranpour, Bahman Salehi, Mina Tabrizi, Masih Tajdini, Ali Ghaleiha, Shahin Akhondzade. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 6. 2014-12-16. PMID:24636461. |
this study aimed to evaluate the efficacy and safety of ddavp nasal spray as an adjunct to risperidone in improving negative symptoms of schizophrenia. |
2014-12-16 |
2023-08-12 |
human |
| Seyed Mohammad Reza Hosseini, Mehdi Farokhnia, Farzin Rezaei, Amirhossein Gougol, Habibeh Yekehtaz, Negar Iranpour, Bahman Salehi, Mina Tabrizi, Masih Tajdini, Ali Ghaleiha, Shahin Akhondzade. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 6. 2014-12-16. PMID:24636461. |
in this randomized double-blind placebo-controlled clinical trial, forty patients aged 18-50 years with a dsm iv-tr diagnosis of chronic schizophrenia and a minimum score of 60 on positive and negative syndrome scale (panss) were equally randomized to receive ddavp nasal spray (20mcg/day) or placebo in addition to risperidone for 8 weeks. |
2014-12-16 |
2023-08-12 |
human |
| Yutaro Suzuki, Takuro Sugai, Shin Ono, Kazushi Sawamura, Naoki Fukui, Junzo Watanabe, Nobuto Tsuneyama, Mami Saito, Toshiyuki Somey. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry and clinical neurosciences. vol 68. issue 5. 2014-12-10. PMID:24405493. |
changes in pr and qtc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. |
2014-12-10 |
2023-08-12 |
Not clear |
| Yutaro Suzuki, Takuro Sugai, Shin Ono, Kazushi Sawamura, Naoki Fukui, Junzo Watanabe, Nobuto Tsuneyama, Mami Saito, Toshiyuki Somey. Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia. Psychiatry and clinical neurosciences. vol 68. issue 5. 2014-12-10. PMID:24405493. |
we examined the difference between the effects of olanzapine (olz) and risperidone (ris) on pr and qt intervals among patients with stable schizophrenia using a cohort analysis. |
2014-12-10 |
2023-08-12 |
Not clear |
| Saeed Shoja Shafti, Parisa Fallah Jahrom. Olanzapine induced Q-Tc shortening. Therapeutic advances in psychopharmacology. vol 4. issue 6. 2014-12-09. PMID:25489475. |
in the present study, safety of olanzapine versus risperidone was compared among a group of patients with schizophrenia to see the frequency of the electrocardiographic alterations induced by those atypical antipsychotics. |
2014-12-09 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatry research. vol 218. issue 1-2. 2014-12-05. PMID:24768247. |
lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. |
2014-12-05 |
2023-08-13 |
Not clear |
| Hiroyoshi Takeuchi, Takefumi Suzuki, Gary Remington, Koichiro Watanabe, Masaru Mimura, Hiroyuki Uchid. Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. Psychiatry research. vol 218. issue 1-2. 2014-12-05. PMID:24768247. |
sixty-one patients with schizophrenia stably treated with risperidone or olanzapine were randomly assigned to dose-reduction-by-half group or dose maintenance group. |
2014-12-05 |
2023-08-13 |
Not clear |
| Mario Di Fiorino, Gino Montagnani, Graziella Trespi, Siegfried Kaspe. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. International clinical psychopharmacology. vol 29. issue 3. 2014-12-03. PMID:24681810. |
extended-release quetiapine fumarate (quetiapine xr) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. |
2014-12-03 |
2023-08-12 |
Not clear |
| Mario Di Fiorino, Gino Montagnani, Graziella Trespi, Siegfried Kaspe. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. International clinical psychopharmacology. vol 29. issue 3. 2014-12-03. PMID:24681810. |
noninferiority of quetiapine xr versus risperidone from baseline to week 12 was assessed by least squares mean (lsm) reduction in the calgary depression scale for schizophrenia (cdss). |
2014-12-03 |
2023-08-12 |
Not clear |
| Mario Di Fiorino, Gino Montagnani, Graziella Trespi, Siegfried Kaspe. Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study. International clinical psychopharmacology. vol 29. issue 3. 2014-12-03. PMID:24681810. |
in this study, quetiapine xr was noninferior to risperidone at reducing depressive symptoms in patients with schizophrenia or schizoaffective disorder. |
2014-12-03 |
2023-08-12 |
Not clear |
| Frédéric Rouillon, Lars Eriksson, Benjaminas Burba, Jiri Raboch, Georgios Kaprinis, Andreas Schreine. Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Acta neuropsychiatrica. vol 25. issue 5. 2014-12-02. PMID:25287730. |
constatre is an open-label, randomised, controlled, relapse prevention trial in patients with stable schizophrenia or schizoaffective disorder switched to risperidone long-acting injectable (rlai) or oral quetiapine, and was designed to test the hypothesis that injectable antipsychotic treatment with risperidone would be more effective than oral therapy with quetiapine. |
2014-12-02 |
2023-08-13 |
Not clear |
| H Y Meltzer, J-P Lindenmayer, J Kwentus, D B Share, R Johnson, K Jayathilak. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Schizophrenia research. vol 154. issue 1-3. 2014-11-26. PMID:24630262. |
a six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. |
2014-11-26 |
2023-08-12 |
Not clear |
| Yuyu Xiong, Zhiyun Wei, Ran Huo, Xi Wu, Lu Shen, Yang Li, Xueli Gong, Zhenqiang Wu, Guoyin Feng, Wenqiang Li, Lin He, Qinghe Xing, Shengying Qi. A pharmacogenetic study of risperidone on chemokine (C-C motif) ligand 2 (CCL2) in Chinese Han schizophrenia patients. Progress in neuro-psychopharmacology & biological psychiatry. vol 51. 2014-11-25. PMID:24495780. |
a pharmacogenetic study of risperidone on chemokine (c-c motif) ligand 2 (ccl2) in chinese han schizophrenia patients. |
2014-11-25 |
2023-08-12 |
Not clear |